While equity analysts predict that Novo Nordisk’s obesity drug sales will reach DKK 40bn (USD 5.9bn) in 2025, the company itself is only forecasting 2025 sales of ”over DKK 25bn (USD 3.7bn, ed.),” CFO Karsten Munk Knudsen tells Danish business daily Børsen.
No one doubts the market potential for weight loss treatments. Even so, a number of uncertainties make it difficult to predict where exactly Novo Nordisk will land in the future. These include the yet-to-be publicized crucial data on tirzepatide, a candidate from Novo Nordisk’s competitor Eli Lilly, and the fact that Wegovy still hasn’t been launched anywhere but the US.